Missed this before I could edit my previous message
---
An early patient experience program is expected to be launched by Botanix in the third quarter of this calendar year to allow highly-qualified patients to gain early access to Sofdra.
The broader launch of Sofdra is expected to follow early in the fourth quarter, with first revenues from sales expected in the period.
---
Who or what is a highly-qualified patient?
Ann: FDA Approves Sofdra, page-252
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $574.9M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1868 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.5¢ | 176419 | 2 |
View Market Depth
| Last trade - 09.45am 28/06/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
Day chart unavailable